Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson’s disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Latest Pharmaceuticals and Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals, Inc. Stock News

As of November 2, 2026, Xeris Biopharma Holdings, Inc. had a $1.9 billion market capitalization, compared to the Pharmaceuticals median of $469.8 million. Xeris Biopharma Holdings, Inc.’s stock is up 29.6% in 2026, down 0.4% in the previous five trading days and up 4.74% in the past year.

Currently, Xeris Biopharma Holdings, Inc. does not have a price-earnings ratio. Xeris Biopharma Holdings, Inc.’s trailing 12-month revenue is $335.4 million with a -5.1% net profit margin. Year-over-year quarterly sales growth most recently was 28.8%. Analysts expect adjusted earnings to reach $-0.090 per share for the current fiscal year. Xeris Biopharma Holdings, Inc. does not currently pay a dividend.

As of November 2, 2026, Amneal Pharmaceuticals, Inc. had a $7.1 billion market cap, putting it in the 73rd percentile of all stocks. Amneal Pharmaceuticals, Inc.’s stock is up 62.2% in 2026, down 2.8% in the previous five trading days and up 104.4% in the past year.

Currently, Amneal Pharmaceuticals, Inc.’s price-earnings ratio is 42.5. Amneal Pharmaceuticals, Inc.’s trailing 12-month revenue is $3.1 billion with a 5.0% net profit margin. Year-over-year quarterly sales growth most recently was 9.9%. Analysts expect adjusted earnings to reach $1.030 per share for the current fiscal year. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
Xeris Biopharma Holdings, Inc.	XERS	D
Amneal Pharmaceuticals, Inc.	AMRX	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Xeris Biopharma Holdings, Inc. has a Growth Score of 30, which is Weak. Amneal Pharmaceuticals, Inc. has a Growth Score of 100, which is Very Strong.

The Growth Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Amneal Pharmaceuticals, Inc. has a more attractive growth grade than Xeris Biopharma Holdings, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Xeris Biopharma Holdings, Inc.	XERS	B
Amneal Pharmaceuticals, Inc.	AMRX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Xeris Biopharma Holdings, Inc. has a Momentum Score of 78, which is Strong. Amneal Pharmaceuticals, Inc. has a Momentum Score of 91, which is Very Strong.

The Momentum Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Amneal Pharmaceuticals, Inc. is considered to have stronger momentum compared to Xeris Biopharma Holdings, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Xeris Biopharma Holdings, Inc.	XERS	F
Amneal Pharmaceuticals, Inc.	AMRX	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Xeris Biopharma Holdings, Inc. has a Earnings Estimate Score of 18, which is Very Negative. Amneal Pharmaceuticals, Inc. has a Earnings Estimate Score of 75, which is Positive.

The Earnings Estimate Revisions Grade Winner: Amneal Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Amneal Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Xeris Biopharma Holdings, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Amneal Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc. Grades

In addition to Estimate Revisions, Growth and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals or Inc. Stock?

Overall, Xeris Biopharma Holdings, Inc. stock has a Growth Score of 30, Momentum Score of 78 and Estimate Revisions Score of 18.

Amneal Pharmaceuticals, Inc. stock has a Growth Score of 100, Momentum Score of 91 and Estimate Revisions Score of 75.

Comparing Xeris Biopharma Holdings, Inc., Amneal Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.